Sotera Health (NASDAQ:SHC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sotera Health (NASDAQ:SHC) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $17.70.

A number of brokerages have recently commented on SHC. Citigroup raised shares of Sotera Health from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $18.00 to $16.00 in a research report on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $20.00 price target on shares of Sotera Health in a research report on Monday, March 4th. Barclays cut their price objective on Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Jefferies Financial Group raised Sotera Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $15.00 to $15.50 in a report on Monday, March 25th. Finally, TheStreet raised shares of Sotera Health from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th.

Insider Transactions at Sotera Health

In related news, Director Pincus & Co. Warburg sold 16,594,363 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the sale, the director now directly owns 88,822,952 shares in the company, valued at approximately $1,271,056,443.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Pincus & Co. Warburg sold 16,594,363 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the transaction, the director now directly owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Michael P. Rutz sold 83,109 shares of Sotera Health stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the completion of the sale, the insider now owns 544,409 shares of the company’s stock, valued at approximately $7,790,492.79. The disclosure for this sale can be found here. 55.12% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sotera Health

Several institutional investors have recently made changes to their positions in SHC. Securian Asset Management Inc. raised its holdings in Sotera Health by 23.0% in the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock valued at $122,000 after acquiring an additional 1,900 shares in the last quarter. Swiss National Bank raised its stake in Sotera Health by 1.0% in the third quarter. Swiss National Bank now owns 217,400 shares of the company’s stock valued at $3,257,000 after purchasing an additional 2,100 shares in the last quarter. Victory Capital Management Inc. lifted its position in Sotera Health by 12.9% during the third quarter. Victory Capital Management Inc. now owns 18,572 shares of the company’s stock worth $278,000 after purchasing an additional 2,117 shares during the period. State of Alaska Department of Revenue grew its stake in Sotera Health by 20.6% during the first quarter. State of Alaska Department of Revenue now owns 13,490 shares of the company’s stock worth $162,000 after buying an additional 2,300 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Sotera Health during the third quarter worth about $58,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Price Performance

NASDAQ:SHC opened at $11.40 on Friday. Sotera Health has a 52-week low of $10.71 and a 52-week high of $19.40. The company has a market cap of $3.23 billion, a P/E ratio of 63.33 and a beta of 2.11. The company has a debt-to-equity ratio of 5.16, a quick ratio of 2.21 and a current ratio of 2.42. The stock’s 50-day simple moving average is $12.99 and its 200 day simple moving average is $14.09.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Sotera Health had a return on equity of 51.32% and a net margin of 4.90%. The firm had revenue of $310.24 million for the quarter, compared to analyst estimates of $302.17 million. During the same quarter in the previous year, the firm earned $0.23 EPS. The business’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, sell-side analysts forecast that Sotera Health will post 0.64 EPS for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.